Medical devices, healthcare technology and the business of care
PMA approval · P150031

VERCISE DEEP BRAIN STIMULATION (DBS)SYSTEM

Boston Scientific Corp · Decision date Dec 8, 2017

FDA DECISIONP150031

What did the FDA approve?

FDA records P150031 as an original PMA application. The recorded decision is approval, dated Dec 8, 2017.

FDA approval order statement

Approval for the Vercise DBS System. The device is indicated for use in bilateral stimulation of the subthalamic nucleus (STN) in the treatment of patients with moderate to advanced levodopa-responsive Parkinsons disease (PD), which is not adequately controlled with medication.
Regulatory pathway
Original PMA
Clinical specialty
Neurology
Decision date
Dec 8, 2017

FDA source record

Regulatory record facts

Identifier
P150031
Regulatory pathway
Premarket approval application
Product code
NHL
Decision code
APPR
Decision date
Dec 8, 2017
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Stimulator, electrical, implanted, for parkinsonian symptoms.

Product code
NHL
FDA device class
3

The approval statement above describes the scope recorded for this original decision. Later supplements may change the device or its indications.

FDA decision timeline

  1. P150031 received

    Application receipt date recorded by FDA.

  2. P150031 · FDA decision

    APPR

  3. P150031/S084 · Related supplement

    VERCISE DEEP BRAIN STIMULATION (DBS) SYSTEM

  4. P150031/S098 · Related supplement

    Vercise Genus DBS Systems; Vercise Gevia DBS Systems

  5. P150031/S102 · Related supplement

    Vercise Deep Brain Stimulation (DBS) Systems

Timeline entries are records held by MedtechLedger for P150031. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P150031

Product / regulatory recordCompanyPathwayDecision dateSource
Boston Scientific CorpPMA supplementSep 13, 2026FDA
Boston Scientific CorpPMA supplementSep 22, 2026FDA
Boston Scientific CorpPMA supplementOct 15, 2026FDA
Boston Scientific CorpPMA supplementOct 30, 2026FDA

Explore the linked device profile

Regulatory context

An original PMA is a premarket approval application. The recorded approval scope is described in FDA’s order and supporting documents.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Boston Scientific Corp

Headquarters
Not reported
FDA applicant address
25155 Rye Canyon Loop, Valencia, CA, 91355

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records